CGTS Corp. Revenue and Competitors

Claim your profile

Miami, FL USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • CGTS Corp.'s estimated annual revenue is currently $9M per year.(i)
  • CGTS Corp.'s estimated revenue per employee is $136,432

Employee Data

  • CGTS Corp. has 66 Employees.(i)
  • CGTS Corp. grew their employee count by -1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.2M353%N/AN/A
#2
$3.8M320%N/AN/A
#3
$9.4M69-3%N/AN/A
#4
$3.9M33-54%N/AN/A
#5
$4.3M369%N/AN/A
#6
$4.9M4018%N/AN/A
#7
$37.5M22675%N/AN/A
#8
$15.4M1029%N/AN/A
#9
$0.7M9N/AN/AN/A
#10
$34.9M2117%N/AN/A
Add Company

CGTS CORP INC. and its affiliated companies are specialized in design and implementation of high complexity technological solutions oriented to specific applications, using state-of-the-art technology, continuous innovation and proven quality in processes and results. The companies that make up the CGTS Corp. group are organized around three fundamental business areas: Intelligent and integrated information systems, biometric solutions and complete solutions on VoIP platform.

keywords:N/A

N/A

Total Funding

66

Number of Employees

$9M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CGTS Corp. News

2022-04-13 - Labcorp Enhances Cell and Gene Therapy Development ...

... Inc. (Xcellbio), a leading developer of cell and gene therapy ... CGTs modify a person's genes to treat disease by inactivating or...

2022-04-13 - Korea's GC inks deal to secure US cell and gene therapy ...

... moved to acquire 100% of the shares of BioCentriq, Inc, a US CDMO that designs and develops scalable cell and gene technologies (CGTs).

2022-03-30 - Cell-Gene Therapy Market Emerging Rapidly - Businesskorea

Cell-gene therapeutics (CGTs) are emerging in the biotech industry and an ... Samsung Biologics and Samsung Venture Investment Corp.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.8M6620%N/A
#2
$9M6616%N/A
#3
$3.5M66-6%N/A
#4
$13.2M6629%$10M
#5
$16.6M6618%N/A